HealthQuill FDA
Almost a year after rejecting approval for ImmunityBio’s combination therapy to treat a type of bladder cancer the USFDA has given the green light to the company’s Anktiva treatment.
Drugs Health Pharma

USFDA grants approval for ImmunityBio’s bladder cancer drug

HQ Team April 23, 2024: Almost a year after rejecting approval for ImmunityBio’s combination therapy to treat a type of bladder cancer the.

Read More
A bacteria that causes infections, including pneumonia, bloodstream infections, and meningitis are being treated by doctors with less effective old generic antibiotics — even though the US regulator has cleared seven next-generation antibiotics to deal with the germs.
Drugs Health Pharma

US doctors still prescribe old generic antibiotics, cost main factor

HQ Team April 20, 2024: A bacteria that causes infections, including pneumonia, bloodstream infections, and meningitis are being treated by doctors with less.

Read More
Anglo-Swedish drugmaker, AstraZeneca will acquire clinical-stage Fusion Pharmaceuticals for $2 billion in cash to get access to the latter’s radioconjugates to treat cancer.
Drugs Medical Pharma

FDA’s accelerated approval of cancer drugs is hasty and doubtful, says new report

HQ Team April 10, 2024:  A new study has found that cancer drugs that got accelerated approval under the US Federal Drug Approval.

Read More
Amylyx Pharmaceuticals announced it has started a process with the USFDA and Health Canada to voluntarily discontinue the marketing authorisations for its amyotrophic lateral sclerosis (ALS) therapy after the drug failed in a last-stage trial.
Drugs Health Pharma

Amylyx Pharma pulls out ALS therapy drug from US, Canada

HQ Team April 4, 2024: Amylyx Pharmaceuticals announced it has started a process with the USFDA and Health Canada to voluntarily discontinue the.

Read More
The USFDA approved Swiss-based Basilea Pharmaceutica International’s Zevtera injection for the treatment of staphylococcus aureus bloodstream infections and skin infections in adults and community-acquired bacterial pneumonia in patients three months to 18 years, and adults. 
Drugs Health Pharma

Swiss-based Basilea Pharmaceutical’s antimicrobial drug gets FDA nod 

HQ Team April 4, 2024: The USFDA approved Swiss-based Basilea Pharmaceutica International’s Zevtera injection for the treatment of staphylococcus aureus bloodstream infections and.

Read More
The US regulator, the Food and Drug Administration plans to ban electrical stimulation devices due to “unreasonable and substantial risk” of illness or injury.
Drugs Medical Pharma

FDA attempts a second time to ban electrical stimulation devices

HQ Team March 26, 2024: The US regulator, the Food and Drug Administration plans to ban electrical stimulation devices due to “unreasonable and.

Read More
The US Food and Drug Administration has cleared Orchard Therapeutics’s gene therapy to treat a disease affecting the brain and nervous system in children — the regulator’s first ever for the disorder.
Drugs Health Pharma

FDA green lights first-ever therapy for rare genetic disease in kids

HQ Team March 19, 2023: The US Food and Drug Administration has cleared Orchard Therapeutics’s gene therapy to treat a disease affecting the.

Read More
Pfizer Inc., announced that a late-stage study on its Adcetris drug, for treating the most common lymphoma, yielded positive results and improved overall survival rates.
Drugs Health Pharma

Pfizer says trials on lymphoma drug ‘positive,’ extends life of patients 

HQ Team March 12, 2024: Pfizer Inc., announced that a late-stage study on its Adcetris drug, for treating the most common lymphoma, yielded.

Read More
The FDA has issued revised draft guidance for early treatment of Alzheimer’s disease with drugmakers told to focus on medicines that are likely to predict a clinical benefit.
Drugs Health Pharma

FDA issues revised drug guidelines for early Alzheimer’s disease

HQ Team March 12, 2024: The FDA has issued revised draft guidance for early treatment of Alzheimer’s disease with drugmakers told to focus.

Read More
The FDA has approved Pfizer’s Besponsa drug for pediatric patients aged one year and above to treat acute leukaemia.
Drugs Health Pharma

Pfizer’s pediatric leukaemia drug gets regulator FDA’s green light

HQ Team March 7, 2024: The FDA has approved Pfizer’s Besponsa drug for pediatric patients aged one year and above to treat acute.

Read More